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The detailed molecular basis and determinants of in vivo tumour sensitivity to conventional anticancer agents remain unclear. We
examined the cellular and molecular consequences of cisplatin treatment using two ovarian tumour xenograft models that had not
been previously adapted to culture in vitro. Both xenografts were curable with clinically relevant multiple doses of cisplatin. Following a
single dose of cisplatin (6mgkg
 1i.p.) growth delays of 25 and 75 days were obtained for pxn100 and pxn65, respectively. This
difference in response was not due to differences in DNA damage. Pxn100 tumours had a functional p53 response and a wild-type
p53 sequence, whereas pxn65 harboured a mutant p53 and lacked a functional p53 response. Microarray analysis revealed the
induction of p53-regulated genes and regulators of checkpoint control and apoptosis in pxn100 tumours following cisplatin-
treatment. By contrast, there was no p53-dependent response and only limited changes in gene expression were detected in the
pxn65 tumours. TUNEL analysis demonstrated high levels of apoptosis in the pxn100 tumours following cisplatin treatment, but
there was no detectable apoptosis in the pxn65 tumours. Our observations show that a marked in vivo response to cisplatin can
occur via p53-dependent apoptosis or independently of p53 status in human ovarian xenografts.
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cis-Diamminedichloroplatinum(II) or cisplatin (CDDP) is an
important anticancer agent widely used to treat many malignancies
and is the single most effective chemotherapeutic agent used in the
treatment of ovarian cancer (reviewed by Chu, 1994; Adams et al,
1998). The major mechanism of CDDP cytotoxicity is considered
to result from DNA damage caused by the formation of DNA
adducts, including inter- and intrastrand crosslinks. The principle
mechanisms that translate CDDP-induced DNA damage into
cytotoxicity are not understood, although there is considerable
evidence that CDDP treatment can induce a cell cycle arrest and/or
apoptosis (Eastman, 1999).
Several factors are reported to influence sensitivity or response
to CDDP-treatment, including intracellular drug uptake, DNA
binding and repair as well as thiol binding (reviewed in Kartalou
and Essigmann, 2001) However, the role of the p53 tumour
suppressor gene has been of particular interest in attempts to
understand the cellular response to anticancer agents such as
CDDP, as it has been demonstrated that functional p53 is required
for induction of apoptosis in lymphoid tumours and transformed
primary cell line models following genotoxic damage induced by
cytotoxic drugs or irradiation (Lowe et al, 1993; Komarova et al,
1997). p53 is the most frequently mutated tumour suppressor in
human malignancy and mutations have been detected in 40–80%
of ovarian cancers (Reles et al, 2001). However, its role in
determining sensitivity of ovarian cancer cells to CDDP remains
unclear as the literature shows that the presence or absence of p53
can cause resistance, sensitivity or have no effect (Brown et al,
1993; Eliopoulos et al, 1995; Herod et al, 1996; Wu and El-Deiry,
1996; De Freudis et al, 1997; O’Connor et al, 1997; Pestell et al,
1998, 2000).
Another factor that influences response to CDDP is the capacity
to undergo apoptosis. Treatment of ovarian cancer cells results in
the induction of apoptosis following a robust activation of Jun N-
terminal protein kinases by c-ABL, a response not seen in resistant
cells (Hayakawa et al, 1999; Gebauer et al, 2000). Activation of c-
ABL by CDDP requires the ATM protein, DNA-PK and a
functional DNA mis-match repair response (Kharbanda et al,
1998). Expression of the BCL-2 family of pro- and anti-apoptotic
genes also affects the apoptotic response following CDDP
treatment; however, again in human ovarian cancer the evidence
is contradictory (Eliopoulos etal, 1995;Herod et al, 1996; Perog et al,
1996; Wu and El-Deiry, 1996; Jones et al, 1998; Beale et al,2 0 0 0 ) .
The translation of molecular mechanisms of action of anticancer
agents from in vitro tissue culture models to tumours in vivo can
be challenging. In vitro tissue culture models are extremely useful
for examining the response of ovarian cancer cells to CDDP and
play a role in dissecting molecular events following exposure to
CDDP. Comparison of ovarian tumours treated in vivo and in vitro
with CDDP have demonstrated that their relative sensitivity
observed in vitro is preserved in vivo (Kelland et al, 1992).
However, use of tumour cells that have been adapted to growth on
a plastic surface may have limitations as it is frequently necessary
Revised 12 July 2004; accepted 6 August 2004; published online
28 September 2004
*Correspondence: Dr MI Walton; E-mail: Mike.Walton@icr.ac.uk
2Contributed equally to this study.
British Journal of Cancer (2004) 91, 1614–1623
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sto employ concentrations considerably higher than those achieved
in patients to detect measurable effects in vitro (eg Vermorken
et al, 1984; Potapova et al, 1997). Moreover, in vitro approaches to
understand factors that influence response to anticancer agents
commonly generate degrees of resistance factors that are higher
than that observed in patients (De Graeff et al, 1988; Teicher et al,
1991). Several studies have also noted that CDDP-resistant
tumours established by in vivo treatment with CDDP show
acquired resistance in three-dimensional spheroid in vitro
cultures, but not when cultured as monolayers in vitro (Teicher
et al, 1990; Kobayashi et al, 1993).
In this study we set out to explore the molecular events
following a robust response to CDDP in vivo, using two sensitive
human ovarian cancer xenograft models. These xenografts were
selected deliberately because they were curable by multiple
clinically relevant doses of CDDP, had not been previously adapted
to in vitro culture conditions and could not be passaged in vitro.
We describe the measurement of molecular events following
exposure to a single treatment with CDDP and demonstrate that a
marked therapeutic response to CDDP occurs in the p53 wild-type
tumour with evidence of apoptosis. Moreover, we also demonstrate
an even greater response in a tumour that harbours mutant p53
and does not exhibit detectable apoptosis. Hence, in vivo
sensitivity of ovarian cancers to CDDP can occur in the presence
or absence of both a p53-dependent response and also of
apoptosis.
MATERIALS AND METHODS
Tumour xenografts
All animal studies were carried out in accordance with UKCCCR
guidelines and after independent ethical committee approval
(Workman et al, 1998). Animals were housed in Maxi-miser PIV
(positive individual ventilated) caging systems (Thoren, Hazleton,
Pennsylvania, USA) and maintained on a Labsure 21% protein diet
with access to tap water ad libitum. The pxn65 xenograft was
derived from a moderately differentiated adenocarcinoma and was
epithelial in origin. By contrast, the pxn100 xenograft was derived
from an endodermal sinus tumour and was germ cell in origin.
Their xenograft histologies reflected those of the tumour of origin
(Harrap et al, 1990). The pxn65 and pxn100 human ovarian cancer
xenografts were passsaged as or grown for treatment from 2mm
3
biopsy fragments implanted s.c. in anaesthetised female nude
(random bred) mice (age 6–8 weeks). Mice bearing comparable
sized tumours (approx 8mm
3 diameter) were randomised into
treatment groups or control groups. Cisplatin (Sigma-Aldrich,
Gillingham, Dorset, UK) was dissolved in 0.9% saline immediately
prior to use. For antitumour studies treatment was a single i.p.
dose of 6mgkg
 1 CDDP and tumour diameters were measured
every 7 days. For other studies, where indicated, mice were
irradiated with 5Gy from a
60Co source. Tumours were rapidly
removed from mice and a portion immediately snap frozen on dry
ice or homogenised in lysis buffer, prior to analysis.
Measurement of CDDP-induced DNA adducts by
quantitative-PCR
Genomic DNA was extracted from tumour samples by incubation
for 2h at 561C in extraction buffer (100mM NaCl, 50mM Tris HCl
pH 7.6, 1% SDS, 50mM EDTA pH 8.0, 100mgml
 1 proteinase K).
DNA was recovered by the addition of an equal volume of 5 M LiCl
and two volumes of chloroform. The aqueous phase was recovered
and DNA was precipitated by the addition of two volumes of
absolute ethanol and quantified spectrophotometrically at 260nm.
Quantification and integrity of genomic DNA was confirmed by
electrophoresis of 1mg on a 0.6% agarose gel. A quantitative-PCR
approach was used to measure DNA adducts on the genomic DNA
of the treated tumours as Taq DNA polymerase cannot progress
past certain DNA-CDDP adducts (Grimaldi et al, 1994). The assay
employed two primers (NRAS1-50-CCT AAA TCT GTC CAA AGC
AGA GGC-30, NRAS2-50-CAG CAA GAA CCT GTT GGA AAC
CAG-30) that yielded a 523bp of the first intron/exon of N-RAS.
Calibration experiments determined that 25 cycles of 1min at
941C, 1min at 651C and 2min at 721C were optimal for
quantification (data not shown). Briefly, 0.5mg of genomic DNA
was amplified with 1mM primers, one of which, NRAS1, had been
end-labelled by incubation with polynucleotide kinase and
[g
32P]ATP (Clarke, 1999). Products were separated on a denaturing
6% polyacrylamide gel containing 8 M urea, vacuum dried onto
Whatman No. 1 paper and the product quantified by
phosphorimaging using a Molecular Dynamics Storm phosphor-
imager (Amersham Biosciences UK Ltd, Little Chalfont,
Buckinghamshire, UK).
Immunoblotting
Xenografts were removed and homogenised in lysis buffer (150mM
NaCl, 50mM Tris, 1% NP40, 0.2% SDS, 1mM PMSF, 10mgml
 1
aprotinin, 10mgml
 1 leupeptin and 1mM sodium orthovanadate).
Protein concentration was determined using a BCA protein assay
(Pierce Biotechnology Inc., Rockford, IL, USA). Samples (100mg)
and Rainbowt molecular weight markers (Amersham Biosciences
UK Ltd, Little Chalfont, Buckinghamshire, UK) were separated by
electrophoresis on polyacrylamide gels and electro-transferred
onto Hybond-c nitrocellulose membranes (Amersham Biosciences
UK Ltd, Little Chalfont, Buckinghamshire, UK). To avoid potential
cross-reaction with host stroma and infiltrating host lymphocytes,
immunoblots were probed with non-rodent antibodies. Immuno-
blots were blocked with 5% non-fat milk in TBST (10mM Tris HCl
pH 7.6, 142mM NaCl, 0.1% Tween-20) and then incubated with a
1:5000 dilution of anti-Rho-GDI/D4 rabbit polyclonal antibody
that recognises the full length and cleaved protein, 1:1000 dilution
of an anti-procaspase 3 rabbit polyclonal or 1:1000 dilution of
anti-bax rabbit polyclonal antibody (BD Biosciences Pharmingen,
San Diego, CA, USA). Specific antigen-antibody interaction was
detected with a horseradish peroxidase-conjugated anti-rabbit IgG
using enhanced chemiluminscence Western blotting detection
reagents (Amersham Biosciences UK Ltd, Little Chalfont, Buck-
inghamshire, UK).
RNA analysis
Xenografts were removed and homogenised in 4 M guanidine
thiocynate, 3 M sodium acetate pH 6.0, and 0.12 M b-mercaptoetha-
nol. Total RNA was recovered by centrifugation through a 5.7 M
caesium chloride gradient followed by ethanol precipitation. Total
RNA (20mg) was separated on a 1.2% agarose gel in the presence of
formaldehyde and transferred by capillary action onto nylon
Hybond-N membrane (Amersham Biosciences UK Ltd, Little
Chalfont, Buckinghamshire, UK). RNA was fixed by baking at 801C
for 2h and UV crosslinking at 1200Jm
 2. P21
waf1/cip1 full-length
cDNA (2.12kb), MDM2 (0.9kb fragment) and rat GAPDH cDNA
fragment (1.3kb) were labelled by random priming in the presence
of [a
32P]dCTP (Amersham Biosciences UK Ltd, Little Chalfont,
Buckinghamshire, UK). Probes were separated from unincorpo-
rated dNTPs using Microspint S-300 HR columns (Amersham
Biosciences UK Ltd, Little Chalfont, Buckinghamshire, UK),
hybridised using the method of Church and Gilbert (1984) and
the signal detected by direct autoradiography.
Single-stranded, high-specific activity antisense RNA probes for
human Caspase 8, Fas-ligand, Fas-receptor, FADD, BCL-W, BCL-X,
BFL-1, BID, BIK, BAK, BAX, BCL-2, MCL-1, RPL32 and GAPDH
(BD Biosciences Pharmingen, San Diego, CA, USA) were prepared
by in vitro transcription in the presence of [a
32P]-UTP (Clarke,
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s1999). RNase protection was performed on 10mg of total RNA as
described previously (Ross et al, 2001). Protected fragments were
separated by electrophoresis on denaturing 5% polyacrylamide/7M
urea gels, the gels were transferred to Whatmann No. 1 paper and
vacuum dried. Protected probe fragments were detected and
quantified by phosphorimaging using a Molecular Dynamics
Storm phosphorimager and ImageQuant software (Amersham
Biosciences UK Ltd, Little Chalfont, Buckinghamshire, UK).
The expression levels of 256 genes whose products are involved
in the regulation of cell death and the cell cycle were profiled using
a commercially available nylon microarray (BD Biosciences
Clontech, Palo Alto, CA, USA). Poly(A)
þ mRNA was prepared
from total RNA using oligo(dT) cellulose (Invitrogen, Carlsbad,
CA, USA). In total, 1mg of Poly(A)
þ mRNA was labelled for 25min
at 501C by reverse transcription with MMLV reverse transcriptase
from gene-specific primers in the presence of [a
32P]dATP
(Amersham Pharmacia Biotech UK Ltd, Little Chalfont, Buck-
inghamshire, UK). Unincorporated nucleotides were removed
using Chromaspin-200 columns (BD Biosciences Clontech, Palo
Alto, CA, USA). The labelled probes were denatured for 20min at
681C in 0.1mM NaOH, 1mM EDTA, neutralised by the addition of
an equal volume of 0.5 M NaH2PO4 pH 7.0, 1mgml
 1 Cot-1 DNA
for a further 10min at 681C and added to microarrays
prehybridised for 30min at 681C with 5ml ExpressHyb containing
0.1mgml
 1 sheared salmon testes DNA. Hybridisation was
overnight at 681C and membranes were washed to a final
stringency of 0.1  SSC, 0.5% SDS at 681C. Hybridisation signals
were detected and quantified by phosphorimaging (Molecular
Dynamics Storm phosphorimager, Amersham Biosciences UK Ltd,
Little Chalfont, Buckinghamshire, UK). Gene exposures were
normalised using all of the seven housekeeping genes found on
the membrane: Ubiquitin, (UBQ), M26880; 14-3-3-zeta (YWHAZ),
M86400; hypoxanthine phosphoribosyltransferase 1 (HPRT1),
V00530; GAPDH (GAPH), XO1677; Tubulin-alpha ubiquitous,
(K-ALPHA-1), K00558; HLA-C4-alpha (HLAC) M11886; Beta-actin
(ACTB), X00351; 23kDa highly basic protein, X56932; Ribosomal
protein S9 (RPS9) U14971 (trivial name; abbrevated name;
Genebank Accession number). The median values of the 24h
treated samples were divided by the median of the 0h controls and
the ratios presented in Table 1.
TUNEL assay
The TUNEL method was used to detect apoptosis in situ. Terminal
deoxyncleotidyltransferase binds 30 hydroxy termini of DNA
formed during apoptosis and will catalyse the addition of
biotinylated-deoxynucleotides. Tumours were removed, fixed in
methocarne, paraffin-embedded and 12.5mM thick sections cut.
The sections were de-paraffinised in Histoclear, rehydrated in Tris-
buffered saline, permeabilised by incubation with 20mgml
 1
Table 1 Gene expression affected by 42.5-fold following 6mgkg
 1i.p. CDDP
Acc. no. Gene name pxn65 pxn100 Comments
X56932 Ribosomal protein L13a (RPL13A) 0.187 1.741 Component of the 60S ribosomal subunit
K00558 Tubulin-alpha (TUBA1) 0.257 2.261 Ubiquitous tubulin isoform, member of a family of microtubule structural proteins
AF001954 Inhibitor of growth family, member 1
(ING1)
0.258 1.330 Required for optimal p53 function, can mediate growth arrest, senescence and
apoptosis
AF017988 Secreted frizzled-related protein 5 (SFRP5) 0.280 2.625 Secreted apoptosis-related protein family member, may modulate of Wnt signalling
U14971 Ribosomal protein S9 (RPS9) 0.327 1.147 Component of the small 40S ribosomal subunit
AF017986 Secreted frizzled-related protein 2 (SFRP2) 0.340 0.109 Secreted apoptosis-related protein family member, may modulate of Wnt signalling
M14505 Cyclin-dependent kinase 4 (CDK4) 0.362 1.124 Required for cell cycle progression, phosphorylates and inactivates pRb
M15796 Proliferating cell nuclear antigen (PCNA) 0.387 5.863 Processivity factor for DNA polymerases d and e. Role in DNA repair synthesis
M62402 IGFBP6 insulin-like growth factor-binding
protein 6
1.101 28.76 Binds and modulates insulin-like growth factor activity
AF010310 Proline dehydrogenase 1 (PRODH1/PIG6) 1.069 9.289 Generates reactive oxygen species following p53-induction
U22398 Cyclin-dependent kinase inhibitor 1C
(CDKN1C/p57/Kip2)
0.513 7.714 Inhibits several G1 cyclin/Cdk complexes, overexpression arrests cells in G1
U90313 Glutathione transferase omega
(GSTTLp28)
0.722 6.236 May bind glutathione, but has no transferase or peroxidase activity
AF010314 Ectodermal-neural cortex (ENC1/PIG10) 0.992 5.616 Nuclear matrix-associated phosphoprotein, binds actin and interacts with active pRb
L22474 BCL2-associated X protein (BAX) 0.542 4.428 Pro-apoptotic bcl-family member, required for apoptosis induced by chemotherapeutics
U10564 WEE1+homolog (WEE1) 0.676 4.293 Tyrosine kinase, negatively regulates entry into mitosis, phosphorylates cdc2/cyclin B
M11886 MHC, class I, C (HLA-C) 0.833 4.190 Role in the immune system, presents peptides derived from endoplasmic reticulum
M26880 Ubiquitin C (UBC) 0.504 4.134 Polyubiquitin protein precursor that marks cellular proteins for degradation
AF010309 Quinone oxidoreductase homolog (PIG3) 0.898 3.611 Quinone oxidoreductase homologue, long-lived reporter of p53 induction
M25753 Cyclin B1 (CCNB1) 0.671 3.097 G2M cyclin, binds cdc2 to form the maturation-promoting factor
M34065 Cell division cycle (CDC25C) 1.325 2.913 Protein tyrosine phosphatase; dephosphorylates cdc2/cyclin B and triggers mitosis
Y00285 IGF2R insulin-like growth factor 2 receptor 0.949 2.822 Mediates signal transduction
U77949 Cell division cycle 6 homolog (CDC6) 0.661 2.692 Regulates early steps of DNA replication, binds PCNA and ATM-dependent
checkpoint
U23765 BCL2-antagonist/killer 1 (BAK1) 0.768 2.643 Pro-apoptotic BCL-family member, required for apoptosis induced by
chemotherapeutics
U69611 Disintegrin and metalloproteinase domain
17 (ADAM17)
0.989 2.526 TNF-a converting enzyme, binds mitotic arrest deficient 2 protein
L31951 Mitogen-activated protein kinase 9
(MAPK9/JNK2)
0.967 0.366 Jun N-terminal kinase, binds p53 and increases its t1/2 in non-stressed cells
AF010312 LPS-induced TNF-alpha factor (PIG7) 1.445 0.274 LPS-induced TNF-alpha factor; functions as a transcription factor
U34819 Mitogen-activated protein kinase 10
(MAPK10/JNK3)
1.733 0.222 Jun N-terminal kinase activated by apoptosis signal related kinase 1
M35410 Insulin-like growth factor binding protein 2
(IGFBP2)
0.511 0.155 Binds and modulates insulin-like growth factor activity
Italic text indicates genes reported to be transcriptionally regulated by p53. Bold text highlights gene expression altered by 42.5-fold. The columns headed pxn65 and pxn100
are ratios of CDDP-treated gene expression relative to pretreatment control.
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sproteinase K for 30min at 371C and endogenous peroxidases were
inactivated by incubation in 3% H2O2 for 5min. The slides were
equilibrated for 30min in TUNEL equilibration buffer (Calbio-
chem, San Diego, CA, USA) and then incubated at 371Ci na
humidified chamber for 90min with a TUNEL labelling mix
containing terminal deoxyncleotidyltransferase. Slides were
blocked for 10min at room temperature and incubated with
streptavadin-horse radish peroxidase conjugate for 30min at room
temperature. Slides were washed in Tris-buffered saline and
incubated with DAB substrate for 15min. Slides were counter-
stained with methyl green. HL-60 cells treated with actinomycin D
in vitro were included as a positive control for apoptosis (data not
shown).
RESULTS
Choice of human ovarian cancer model and response to
CDDP
A previous study of 16 ovarian tumours established as in vivo
xenograft tumours direct from tumour biopsy material had
established their relative sensitivity to treatment with four
platinum-based agents (Harrap et al, 1990). Two of the 16
tumours, pxn65 and pxn100, were found to be highly chemosensi-
tive and curable following treatment with multiple doses of CDDP
close to those commonly used in the clinic (Harrap et al, 1990 and
unpublished). The majority of ovarian cancers are epithelial in
origin and pxn65, derived from a moderately differentiated
adenocarcinoma, belonged to this class. The biopsy was derived
from a previously untreated patient who went on to show a
complete remission with CDDP (Harrap et al, 1990). Pxn100 was
derived from an endodermal sinus tumour and was germ cell in
origin. This biopsy was taken from a patient who showed complete
remission to a number of platinum-based combination therapies
prior to biopsy (Harrap et al, 1990). These two lines would not
grow as monolayer cultures in vitro and could only be passaged as
in vivo xenografts where their response and histopathology as a
xenograft closely paralleled that observed in the clinic (Harrap
et al, 1990). Therefore, pxn65 and pxn100 provided a valuable
opportunity to study cellular and molecular events associated with
CDDP treatment in highly sensitive, curable, in vivo models of
human ovarian cancer.
Although both tumours responded to CDDP treatment, pxn100
was less sensitive as a greater number of treatments and a higher
total dose (8mgkg
 1i.p. on days 0, 7, 14 and 28) were required to
achieve a cure in pxn100 xenografted mice compared to pxn65
(6mgkg
 1i.p. on days 0, 49 and 77 Harrap et al, 1990 and
unpublished). The different regimes required to achieve a cure
would potentially complicate efforts to measure and compare
responses following CDDP-treatment. Our aim here was to
measure the early cellular and molecular events following CDDP
treatment. Importantly, CDDP is rapidly sequestered by protein-
binding, such that 60min after administration no free drug
remains in the plasma (Siddik et al, 1987). Therefore, with a single
i.p. dose of 6mgkg
 1 we would be measuring response to a brief
genotoxic insult induced by CDDP-treatment at a dose close to that
administered in the clinic (the clinical dose is equivalent to
approximately 2.5mgkg
 1). Both tumours initially responded to
this treatment regimen. Pxn65 tumours did not show evidence for
reduced relative tumour volume until day 14 (53.5%) and a nadir
of 6% was seen at day 35 (Figure 1). Pxn100 tumours showed
evidence for reduced tumour volume 7 days following treatment
with a minimum relative tumour volume of 46.4%. Pxn100
tumours exhibited a 25-day growth delay, whereas pxn65 tumours
had a 75-day growth delay (Figure 1). This observation was
surprising as the germ-line pxn100 tumour might be expected to
be more sensitive to CDDP-treatment than the epithelial-derived
pxn65 tumour (Ozols and Vermorken, 1997). The doubling times
for the control tumours were similar at 5.0 and 5.8 days,
respectively (Figure 1) and comparable to previous observations
(Harrap et al, 1990). Therefore, differences in tumour growth rate
were unlikely to account for their relative sensitivity to CDDP-
treatment.
Differential sensitivity to single dose CDDP could be explained
by differences in CDDP exposure, either due to reduced drug
uptake or increased drug efflux. Alternatively, different DNA
repair responses could influence the amount of DNA damage and
response to this single dose of CDDP. Quantitation of the number
of DNA adducts following treatment of the two tumours provides
an estimate of the relative exposure to CDDP and the rate of DNA
repair. To achieve this we used a quantitative-PCR approach to
measure DNA adducts on the genomic DNA of the CDDP-treated
tumours (Grimaldi et al, 1994; Koberle et al, 1996). Briefly, the
quantitiative PCR-based assay involved amplifying a conserved
523bp fragment of the N-RAS gene. DNA adducts will physically
obstruct the polymerase and reduce product yield until the lesions
have been removed or repaired. Decreased yields of the 523bp
PCR product, as a result of the formation of CDDP-adducts, were
detected at 8h (53% of pretreatment control) following CDDP
treatment of pxn100 tumours (Figure 2). The yield of PCR product
was similar at 16h (63% of control) and 24h (44% of control), but
had increased to 88% of the pretreated controls by 48h suggesting
that DNA damage repair processes were active. The number of
DNA adducts detected in the pxn65 tumours was no greater than
pxn100 tumours and at 48h the yield of PCR product from CDDP-
treated pxn65 (72% of control) and pxn100 tumours (88% of
control) were similar. This implied that increased DNA-adduct
formation and by extrapolation increased exposure to CDDP are
unlikely to have contributed to the increased sensitivity of the
pxn65 tumour. Although differences in inter- and intrastrand
crosslinks as well as longer-term differences in DNA repair after
48h could not be excluded by these data.
P53 status of pxn65 and pxn100 tumours
p53 status has been reported to influence response to CDDP
treatment in a number of models and consequently the p53 status
of these two tumours were determined (Brown et al, 1993;
Eliopoulos et al, 1995; Herod et al, 1996; O’Connor et al, 1997). In
order to determine the functional p53 status in these two tumours
we induced p53 by exposing pxn65 and pxn100 xenografts to
ionising radiation and examined the expression of genes known to
be increased following p53 induction. At 4h after exposure to 5Gy
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Figure 1 Growth curves of pxn65 and pxn100 xenograft tumour
volume relative to pretreatment volume following a single treatment with
CDDP (6mgi.p.kg
 1). Closed circular symbols¼pxn65, open square
symbols¼pxn100, solid line¼control, dotted line¼CDDP; n¼6, error
bars¼s.e.m.
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sg-irradiation P21
waf1/cip1 and MDM2 expression were increased in
pxn100 tumours, but not pxn65 tumours (Figure 3). This indicated
that pxn100 tumours had a functional p53 response that was
absent in pxn65 tumours. To confirm the p53 status of the tumours
we used single-strand conformational polymorphism analysis and
direct sequencing to determine that the pxn100 tumour had a wild-
type p53 sequence and the pxn65 tumour had an insertion of
GTGGTGAG and a deletion of base pair 868 in codon 290 (exon 8)
of p53 (data not shown). This would result in a frame shift and
premature termination at codon 306 that would yield an inactivate
p53. Studies with a number of other DNA damaging anticancer
drugs have demonstrated a clear correlation between p53 status
and response (O’Connor et al, 1997). Previous in vitro studies have
shown conflicting evidence for the role of p53 in CDDP sensitivity
of ovarian cancer cell lines and it is possible that there is a subset
of p53 mutant tumours that are CDDP sensitive. Nevertheless, our
observation that the tumour with an inactivated p53 (pxn65) was
more responsive to CDDP-treatment than the p53 wild-type
(pxn100) tumour warranted further investigation of the molecular
basis for this sensitivity.
Analysis of apoptotic gene expression following CDDP
treatment by RNase protection assay (RPA)
One mechanism by which CDDP has been proposed to induce
apoptosis is through increased expression of the Fas-receptor, a
member of the tumour necrosis receptor superfamily, via
activation of p53 (Muller et al, 1997; Fulda et al, 1998; Seki et al,
2000). RNase protection analysis demonstrated that pxn65 and
pxn100 tumours lacked detectable expression of the Fas-ligand
and Fas-receptor and there was no evidence for induction of their
expression following CDDP treatment (Figure 4). The expression
of the BCL-2 family of genes that regulate apoptosis was also
assayed. No measurable signal was detected for BCL-W, BCL-X,
BFL-1, BID, BIK and BCL-2; however, similar levels of MCL1, BAX
and BAK expression were detected in both tumours (Figure 5).
Following CDDP-treatment, pxn100 tumours exhibited evidence
for increased BAX and BAK expression consistent with wild-type
p53 function. This was time-dependent and reached a maximum of
2.9- and 1.7-fold, respectively, at 48h. In contrast, CDDP-treatment
of pxn65 tumours did not significantly alter BAX and BAK
expression. Increased expression of BAX and BAK may be
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Figure 2 Quantitive PCR analysis of DNA adducts on genomic DNA
from control and CDDP-treated (6mgi.p.kg
 1) pxn65 and pxn100
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NRAS PCR product amplified from genomic DNA taken from duplicate
pxn100 xenograft tumours. (B) Quantification of PCR products from
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symbols, dotted line¼pxn65 and closed circle symbols, solid line¼pxn100
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ssignificant as the products of these genes have been reported to be
involved in the induction of apoptosis following treatment with
anticancer agents (Jones et al, 1998; Ionov et al, 2000; Zhang et al,
2000).
cDNA microarray analysis of cell cycle and apoptosis gene
expression following CDDP treatment
Given the role of p53 in the cell cycle and apoptosis and the
observed increase in expression of genes encoding pro-apoptotic
proteins (BAX and BAK), the RNase protection experiments were
followed up using a cDNA array of 256 genes, the products of
which were specifically associated with cell death or cell cycle
regulation. This cDNA array was used to examine the effects on
gene expression 24h after CDDP-treatment (Figure 6). CDDP
treatment of pxn65 tumours decreased the expression of eight
genes 42.5-fold. These included two genes the products of which
were associated with proliferation (CDK4 and PCNA; Table 1).
However, there was no evidence for the increase in expression of
any genes following treatment of pxn65 tumours with CDDP. In
contrast, CDDP treatment of pxn100 tumours resulted in increased
expression of 18 genes and decreased expression of five genes
42.5-fold (Table 1). These changes included increased expression
of a number of genes known to be induced following activation of
p53 (PIG3, PIG6, PIG10, PCNA and BAX) that were unchanged in
pxn65 cells, an observation consistent with the p53 status of this
tumour. In addition, BAK expression was increased following
CDDP-treatment of pxn100 tumours. The changes in expression of
BAX and BAK detected by microarray were consistent with those
observed by RNase protection (Figure 5). We also noted that
CDDP-treatment of pxn100 tumours induced the expression by
42.5-fold of genes encoding proteins that regulate the G2M cell
cycle checkpoint (WEE1, CCNB1, CDC25C) and a gene encoding a
protein involved in the anaphase promoting complex in mitosis
(CDC6). The largest increase in gene expression was the insulin
growth factor related gene IGFBP6 (28-fold) with a smaller increase
in another IGFBP6 related gene IGF2R (2.9-fold) and a reduction in
the insulin-like growth factor binding protein 2 (IGFBP2).I n
addition, there was a small decrease in two MAPK-related genes
(MAPK9/JNK9 and MAPK10/JNK3).
Assessment of apoptosis following CDDP treatment
The single CDDP treatment substantially reduced tumour size and
induced BAX and BAK expression in pxn100 tumour cells (p53
wild type). The products of these genes are pro-apoptotic and are
involved in the induction of apoptosis by chemotherapeutic agents
(Jones et al, 1998; Ionov et al, 2000; Zhang et al, 2000). Therefore,
we examined the induction of apoptosis by measuring apoptosis-
associated DNA strand breaks using in situ TUNEL analysis
between 0 and 96h post-CDDP-treatment. CDDP-treatment of
pxn100 tumours resulted in high levels of TUNEL staining from
16h onwards (Figure 7A). In contrast, there was no detectable
TUNEL signal at any of the time points following treatment of
pxn65 tumours (mutant p53). The positive signal detected in
pxn100 tumours was unlikely to be a direct result of cisplatin-
induced DNA strand-breaks as they are not recognised by TUNEL
unless coupled to an apoptotic response (Chapman et al, 1995).
Our observation suggested that CDDP was inducing apoptosis in
the pxn100 tumours, but not the pxn65 tumours. To confirm this
observation we examined activation of the apoptotic protease
cascade by measuring cleavage of pro-caspase 3 and a caspase 3
substrate, Rho-GDI, by Western blotting (Figure 7B). Substantially,
decreased levels of pro-caspase 3 were detected 24 and 48h
following treatment in pxn100 tumours only. Similarly, Rho-GDI
was also reduced 24 and 48h after CDDP treatment. These
observations were consistent with the TUNEL data and confirmed
the significant levels of apoptosis detected in the pxn100 tumours,
but not in the pxn65 tumours. In addition, we measured BAX
protein expression, but were unable to detect any significant
change in BAX protein following CDDP-treatment (Figure 7B).
DISCUSSION
Our results show the difference in growth delay in response to
single doses of CDDP could not be ascribed to differences in DNA
damage following treatment as pxn65 had lower levels of detectable
DNA adducts than pxn100 tumours following treatment. Pxn100,
but not pxn65 tumours, were found to have wild type and
functional p53 by sequencing and analysis of p53-regulated gene
expression in response to g-irradiation or CDDP-treatment.
Increased expression of two pro-apoptotic genes, BAX and BAK,
were detected following treatment of pxn100 tumours, but not
pxn65 tumours. These genes have been reported to be involved in
the induction of apoptosis following exposure to anticancer agents
(Jones et al, 1998; Ionov et al, 2000; Zhang et al, 2000). High levels
of apoptosis were detected in pxn100 tumours following CDDP
treatment consistent with a p53-dependent apoptotic response as
expected from this phenotype. By contrast, in the more sensitive
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Figure 5 (A) Analysis of BCL-2 family members by RNase protection
analysis of RNA samples from pretreatment tumours and 24h postcisplatin
treatment (6mgkg
 1i.p.). (B) Time course of CDDP-treatment (expres-
sion normalised to RPL32; open circle, dotted line¼pxn65 tumours; filled
circle, solid line¼pxn100 tumours; n¼3, error bars¼s.e.m.).
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spxn65 tumours, there was no evidence for altered expression of
apoptosis regulatory genes or increased apoptosis up to 96h post-
treatment despite the marked response. Therefore, in this in vivo
model of a curable human ovarian cancer, a robust response to
CDDP could be achieved independently of p53 status and did not
appear to require the induction of apoptosis.
It has been widely accepted that cell death induced by DNA
damage following treatment with anticancer agents is primarily a
result of increased apoptosis, and that cells which evade apoptosis
will be less responsive to treatment. Although it is evident that
defects in apoptosis underpin tumorigenesis and drug resistance,
the overall influence of apoptotic defects upon clinical response
remains unclear, as it is has not been established that the response
of solid tumours in the clinic necessarily involves or requires the
induction of apoptosis (Brown and Wouters, 1999; Johnstone et al,
2002). A simple paradigm suggests that as long as p53 remains
functional, cells damaged by radiation or chemotherapy will either
repair or self-destruct. This is largely true in oncogenically
transformed rodent cells or lymphoid malignancies where the role
of p53 in determining an apoptotic response to radiotherapy or
chemotherapy has been clearly demonstrated (Brown and
Wouters, 1999). However, the role of p53 in the response of solid
tumours to anticancer agents is less clear-cut. To illustrate the
complexity, p53
þ/þ mouse embryo fibroblasts immortalised by
expression or E1A and RAS treated with etoposide rapidly die by
apoptosis, whereas their p53
 /  counterparts do not. However,
longer-term clonogenic assays show no difference in overall
survival (Brown and Wouters, 1999). In vivo experiments with
tumours derived from these isogenic cell lines also demonstrated
massive levels of apoptosis and rapidly reduced tumour volume
following irradiation of the p53
þ/þ tumours. However, the growth
delays for the p53
þ/þ and p53
 /  tumours were identical,
suggesting that the competence to induce an initial apoptotic
response by p53-induction had no effect on the overall response of
the tumour (Brown and Wouters, 1999). Similarly, etoposide
treatment or irradiation of p53 wild-type HCT116 p21
þ/þ or
p21
 /  colorectal carcinoma cells demonstrated increased apop-
tosis in the p21
 /  line, but no difference in clonogenic survival
(Wouters et al, 1997). Expression of the anti-apoptotic BCL-2 gene
in the p21
 /  cell line reduced the level of apoptosis compared to
the parental HCT116 p21
 /  cells following irradiation; however,
again there was no difference in clonogenic survival (Wouters et al,
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s1999). In vivo experiments also illustrated this effect, with p53
wild-type HCT116 p21
 /  cells exhibiting high levels of apoptosis
(90% of the tumour by TUNEL assay) following irradiation.
Expression of BCL-2 eliminated the apoptotic response, but did
not influence the overall response of the tumour as the growth
delay was similar for both tumours (Wouters et al, 1999).
In some respects our observations are comparable to the in vivo
study of Wouters et al (1999). The pxn100 p53 wild-type germ cell
ovarian tumour that might be expected to be CDDP sensitive
exhibited the ‘classical’ response of p53 induction, altered p53-
dependent gene expression and high levels of apoptosis that was
followed by a 50% reduction in tumour volume. We also noted that
CDDP induced the expression of genes encoding proteins that
regulate the G2/M cell cycle checkpoint. Induction of a cell cycle
arrest and a specific cell cycle check point at the boundary of G2
and M phases has been implicated in apoptosis induction
(Eastman, 1999). If the cellular damage induced in G1/S and G2/
M, such as a DNA adduct, is detected but irreparable, cells would
be eliminated via apoptosis to prevent them entering mitosis. This
suggests that following treatment of pxn100 cells, DNA damage is
detected and the cells respond through induction of p53.
Irreparably damaged cells are rapidly eliminated by an apoptotic
mechanism and in the absence of further treatment the remaining
cells survive and the tumour regrows. Subsequent treatments
would prevent the regrowth and cause further cell death
(apoptosis), as is the case with pxn100 xenografts where additional
CDDP treatment on days 7, 14 and 28 results in cure (Harrap et al,
1990). A study examining gene expression by cDNA microarray in
a pair of p53
þ/þ ovarian adenocarcinoma cell lines (KFr and its
acquired CDDP resistant counterpart KFrP200) showed a number
of gene changes (Sakamoto et al, 2001). In particular, CDDP
resistance was associated with elevated GST-pi expression and
increased expression of several insulin growth factor receptor
genes. Sensitivity was associated with expression of certain cell
cycle and apoptosis genes, including BAK and CDC25C (Sakamoto
et al, 2001) both of which were upregulated in pxn100 following
CDDP exposure. CDDP treatment of pxn100 also induced several
members of the insulin growth factor gene family, which have been
implicated in the growth and development of ovarian cancer
(Sawiris et al, 2002). Additionally, the expression of two MAPK-
related JNK genes were decreased by CDDP treatment and this
pathway may be involved in sensing platinum-dependent DNA
damage (Potapova et al, 1997).
Paradoxically, the epithelial pxn65 tumour with a mutant p53
that might, on the basis of some studies, be predicted to be far less
sensitive to CDDP was actually even more sensitive to CDDP than
pxn100 and responded in the absence of functional p53 or
detectable apoptosis. There were few significant or meaningful
changes in genes encoding regulators of the cell cycle or apoptotic
cell death following CDDP treatment in this tumour. Decreased
tumour size was detected later than that observed for pxn100. One
explanation is that these tumours failed to recognise DNA damage
resulting from CDDP treatment or that the loss of p53 resulted in
the tumour cells being unable to respond to the damage. The
absence of p53-dependent cell cycle checkpoint regulation
following treatment would allow the tumours to acquire chromo-
somal damage until the damage was sufficient to result in a mitotic
catastrophe, that is, death as a consequence of mechanical damage
(necrosis) rather than induction of a rapid self-destruct signal
(apoptosis). This would also explain the slow decrease in tumour
volume and the widely spaced dosing of CDDP on days 0, 49 and
77 that were optimal for curing pxn65 tumours (Harrap et al, 1990,
unpublished). Recently, it has been demonstrated that certain
types of DNA damage, such as alkylation, can stimulate extensive
necrotic cell death in vitro without a requirement for functional
p53, BAX/BAK or caspase activation (Zong et al, 2004). The
absence of a requirement for p53 would also be consistent with
clinical studies where p53 status appears to have at best a marginal
effect on response and survival to platinum-based treatment of
ovarian tumours (Lavarino et al, 2000; Reles et al, 2001).
Interestingly, treatment of ovarian cancer patients by reintroduc-
tion of functional p53 into the ovarian cancer cells using an
adenoviral vector, did not improve clinical response to treatment
with carboplatin and paclitaxel, despite preclinical studies showing
promise. One explanation proffered was that expression of a
functional p53 restores the ability to recognise, repair and respond
to treatment-induced DNA damage and effectively attenuates or
neutralises the effects of concomitantly administered drugs
(Zeimet and Marth, 2003).
In conclusion, previous studies of established cell lines have
demonstrated that apoptotic response and overall treatment
sensitivity can be distinct from each other. These observations
refute the paradigm that anticancer agents kill cells predominantly
through apoptosis and cells resistant to apoptosis will be less
responsive to treatment. For the first time we demonstrate, using
two in vivo models of curable ovarian cancer that had not been
previously adapted to tissue culture, that a marked response to a
clinically relevant cytotoxic anticancer agent could be achieved in
the presence, and perhaps more importantly, in the absence of
functional p53 where apoptosis was undetectable. Further in-
vestigation of the role of cell cycle regulation and DNA repair,
together with more detailed and larger microarray studies are
warranted in these two tumour models, which may be valuable for
the exploration of in vivo responses.
pxn65
pxn100
CDDP Control
RhoGDI
Pro-caspase 3
p
x
n
6
5
p
x
n
1
0
0
p
x
n
6
5
p
x
n
1
0
0
p
x
n
6
5
p
x
n
1
0
0
p
x
n
6
5
p
x
n
1
0
0
Bax
A
B
Figure 7 (A) In situ TUNEL analysis of apoptosis in samples from
pretreatment tumours and 24h post-CDDP treatment (6mgkg
 1i.p.).
Nuclei were counterstained with methyl green. A brown nuclear stain
indicates a TUNEL positive apoptotic cell. (B) Immunoblots (100mg
sample loading) showing BAX, pro-caspase 3 and RhoGDI cleavage in
pxn65 and pxn100 tumours 16, 24 and 48h post-CDDP-treatment.
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